Tc Biopharm (holdings) PLC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
TC Biopharm (Holdings) PLC reports the immediate resignations of directors Mark Bonyhadi and Edward Niemzyck, effective June 26, 2024.
TC Biopharm received a delisting notice from Nasdaq due to non-compliance with minimum stockholders' equity requirements, despite a recent warrant exercise that temporarily restored compliance.
TC Biopharm has regained compliance with Nasdaq's minimum stockholders' equity requirement following a warrant exercise that generated approximately $3.1 million in gross proceeds.
TC BioPharm has entered into an agreement for the immediate exercise of existing warrants, generating approximately $3.1 million in gross proceeds and issuing new warrants for future share purchases.
TC BioPharm has entered into a non-binding letter of intent to acquire a private biotech company focused on innovative CAR-T therapies, marking their second such agreement in recent months.
TC BioPharm has signed a non-binding letter of intent to acquire a cell therapy company's assets, including a solid tumor toolkit, an NK cell manufacturing toolkit, and two CAR-NK programs.
TC Biopharm's general shareholder meeting, initially announced on February 19, 2024, was adjourned on March 14, 2024, with a future date to be determined.
TC Biopharm (Holdings) PLC issued 623,750 American Depositary Shares, representing 12,475,000 ordinary shares, after the exercise of outstanding warrants, generating approximately $1.26 million in gross proceeds.
TC Biopharm's CEO, Bryan Kobel, has agreed to defer a portion of his pension benefits, convert another portion into ordinary shares, and has been granted options to purchase American Depositary Shares.
TC Biopharm's board approved new stock option grants for executives and non-employee directors, while cancelling all previously issued options.
TC BioPharm provided a shareholder update, highlighting approximately $11.6 million in cost savings and key milestones including FDA clearance for a Phase 1B AML study.